Slide 1: Q4/Year-End 2021 Corporate Update Conference Call
Sine ED Q4/Year-End 202T Corporate Update Conference:call March 9, 2022 NASDAQ: GOVX
Slide 2: Forward Looking Statements
Forward Looking Statements © Certain statements in this presentation may constitute "forward-looking statements” within the meaning of the Private Securities Litigation Reform Act. These statements are based on management's current expectations and are subject to uncertainty and changes in circumsta
Slide 3: GeoVax Reports 2021 Year-End Financial Results and Provides Corporate Update
Ged ) GeoVax Reports 2021 Year-End Financial Results and Provides Corporate Update Advancing Phase 2 Clinical Trials for Covid-19 and Immuno-Oncology ATLANTA, GA, March 9, 2022—GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against infectious diseas
Slide 4: Goal: Strengthen balance sheet to support 2021 goals and operations
GO AL Strengthen balance sheet to support 2021 goals and operations ACHIEVED * Exclusive licenses for Gedeptin® (immuno- oncology vaccine) + Exclusive licenses for GEO- CMO04s1 (Covid-19 vaccine) Gea + Advanced internal G Vacca Serg tomy” development programs
Slide 5: 2021 What we set out to do. What we did. 2022 What's next.
Slide 6: GeoVax Announces $10 Million Private Placement
<Geovax> GeoVax Announces $10 Million Private Placement ATLANTA, GA, January 14, 2022 — GeoVax Labs, Inc. (Nasdaq: GOVX). a biotechnology company specializing in developing Jbuman vaccines and cancer immunotherapies. announced today tha it has entered into a securities purchase agreement with a sing
Slide 7: Phase 2: Advanced Head and Neck Cancers
Phase 2 : Advanced Head and Neck Cancers + FDA orphan drug status granted + Bring on additional clinical sites to accelerate patient enrollment + Evaluating broader use of Gedeptin in conjunction with Immune Checkpoint Inhibitors (ICIs)
Slide 8: COVID-19 and Variants
COVID-19 and Variants’ ‘ ¢ Achieve clinical development GOAL status within 12-18 months . Licensed GEO-CMO4SI, ACHIEVED Covid-19 vaccine; i currently in two Phase 2 CGevax> trials
Slide 9: Phase 2: For the Immunocompromised
Phase 2: For the Immunocompromised + Ist trial to specifically evaluate a Covid-19 vaccine in patients with weakened immune systems * Direct comparison to the Pfizer/BioNTech MRNA vaccine
Slide 10: Covid Vaccine: GEO-CM04S1 Phase 2: Booster
Geo COVID Vaccine: 7 GEO-CMO4S1 Phase 2: Booster + For healthy population fully vaccinated with an mRNA vaccine + Potential for broader and more durable protection versus a 3rd or 4th MRNA dose MDpeoess?
Slide 11: Financial Update
Financial Update "
Slide 12: Consolidated Statements of Operations Information
GeoVax Labs, Inc. Consolidated Statements of Operations Information (amounts in thousands, except share and per share information) Grant and collaboration revenue Operating expenses Research and development General and administrative Loss from operations. Other income (expense), net Net loss Loss pe
Slide 13: Consolidated Balance Sheet Information
13 GeoVax Labs, Inc. Consolidated Balance Sheet Information (amounts in thousands, except share information) December 31 2021 1020 Assets Cash and cash equivalents $ 11,424 $ 9,884 Other current assets 205 351 Total current assets 11,629 10,235 Property and other assets, net 168 Total assets $ Liabi
Slide 14: Q&A Session
Slide 15: 2022 Focus
CGecvax> Vaccines Serving Humanity 2022 Focus. + Successfully advance the three Phase 2 clinical programs in support of Gedeptin® and GEO-CM04Ss1 + Ensure appropriate resources to support the IND-enabling initiatives of our priority internal programs and operational enhancements and developments
Slide 16: Vaccines Serving Humanity
: Cc Geovaxo Vaccines Serving Humanity